​A Network Model for Early Clinical Development
​Benefits and Lessons Learned
White Paper

Early clinical development (ECD) studies have become increasingly expensive in recent years. One approach to reducing timelines is the design and execution of hybrid clinical trial models in ECD studies, in which both healthy volunteers and patient populations participate. This approach, which is suitable for both small-molecule drugs and biologics (including biosimilars), allows sponsors to begin tracking the impact of their drug on the targeted population to more rapidly confirm early proof of concept. This white paper discusses lessons learned based on IQVIA’s experience with a vast number of ECD studies across the Asia-Pacific region, Europe, and the United States.

You may also be interested in
Contact Us
Contact Us
Contact Us

Email Us

Get in touch today to discover the right solutions for you.

Call Us

We are pleased to speak with you during our standard business hours.

U.S. Toll-Free only
+1 866 267 4479

For international call please find a number in our toll-free list.